FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3200457141> ?p ?o ?g. }

• W3200457141 abstract "ABSTRACT Purpose In the absence of treatments for chemotherapy-induced peripheral neuropathy (CIPN), dose reductions (DR) and premature discontinuation (PD) are primary management strategies. However, decision-making guidance is insufficient and knowledge of factors associated with DR/PD is limited. We examined biopsychosocial factors associated with CIPN-related DR/PD in women undergoing taxane-based chemotherapy for early-stage breast cancer. Patients and methods As part of a longitudinal study of CIPN measurement, women completed assessments before the first taxane infusion and at the final infusion or within the originally expected timeframe for the final infusion. Participants completed self-report measures of CIPN, pain, and physical and psychosocial wellbeing, and underwent physical testing of lower limb disability and Quantitative Sensory Testing for sensation and pain threshold to thermal, vibration, and touch stimuli in the feet and hands. Sociodemographic and clinical data were collected. Logistic regression was used to identify factors associated with neuropathy-related DR/PD. Results Among 121 participants, 66 (54.5%) received taxane-as-prescribed, 46 (38.0%) had neuropathy-related DR/PD, and 9 (7.4%) had DR/PD for other reasons. Factors associated with neuropathy-related DR/PD were receipt of paclitaxel (Odds Ratio [OR]=75.05, 95% Confidence Interval [CI] 2.56-2197.96]), lower pre-treatment pain catastrophizing (OR=0.72, 95% CI: 0.54 – 0.95), and higher post-treatment neuropathic pain (OR=10.77, 95% CI: 1.99 – 58.15) and sensitivity to cold pain in the hand (OR=1.64, 95% CI: 1.05 – 2.56). Conclusion CIPN-related DR/PD is associated with paclitaxel treatment and post-treatment neuropathic pain and cold pain sensitivity in the hands. CIPN communication to healthcare providers may be influenced by pain catastrophizing, suggesting symptom appraisal may be an important factor in communication. Findings could contribute to clinical practice recommendations to facilitate treatment decision-making. Lay summary We studied pre- and post-treatment factors associated with reduced taxane dose or early cessation due to chemotherapy-induced peripheral neuropathy in women undergoing chemotherapy for early-stage breast cancer. Reduced taxane dose or early cessation is associated with paclitaxel treatment, and high post-treatment neuropathic pain and sensitivity to cold pain stimuli in the hands. Communication of these experiences to healthcare providers may be influenced by pre-treatment thoughts and feelings about symptoms. Precis for use in the Table of Contents two concise sentences that state the significant conclusion(s) or message of the manuscript; Chemotherapy-induced peripheral neuropathy-related reduced taxane dose or premature discontinuation is associated with paclitaxel treatment and high post-treatment neuropathic pain and cold pain sensitivity in the upper limbs. Reporting of these experiences may be influenced by pre-treatment symptom appraisal and communication style." @default.
• W3200457141 created "2021-09-27" @default.
• W3200457141 creator A5002305085 @default.
• W3200457141 creator A5004644854 @default.
• W3200457141 creator A5014680930 @default.
• W3200457141 creator A5025969167 @default.
• W3200457141 creator A5034413859 @default.
• W3200457141 creator A5046435463 @default.
• W3200457141 creator A5053322665 @default.
• W3200457141 creator A5057013722 @default.
• W3200457141 creator A5059636930 @default.
• W3200457141 creator A5061541408 @default.
• W3200457141 creator A5061550352 @default.
• W3200457141 creator A5062558520 @default.
• W3200457141 creator A5067759017 @default.
• W3200457141 creator A5068462805 @default.
• W3200457141 creator A5068834073 @default.
• W3200457141 creator A5079760725 @default.
• W3200457141 creator A5080044176 @default.
• W3200457141 creator A5080096322 @default.
• W3200457141 date "2021-09-16" @default.
• W3200457141 modified "2023-10-03" @default.
• W3200457141 title "Factors associated with chemotherapy-induced peripheral neuropathy-related reduced taxane dose or premature discontinuation in women with early-stage breast cancer" @default.
• W3200457141 cites W1614256764 @default.
• W3200457141 cites W1954878513 @default.
• W3200457141 cites W1968122541 @default.
• W3200457141 cites W1976627713 @default.
• W3200457141 cites W1981726399 @default.
• W3200457141 cites W1984689348 @default.
• W3200457141 cites W1986913398 @default.
• W3200457141 cites W2000445173 @default.
• W3200457141 cites W2008902622 @default.
• W3200457141 cites W2016000531 @default.
• W3200457141 cites W2019274382 @default.
• W3200457141 cites W2024995064 @default.
• W3200457141 cites W2026496903 @default.
• W3200457141 cites W2026536960 @default.
• W3200457141 cites W2030219471 @default.
• W3200457141 cites W2030840471 @default.
• W3200457141 cites W2037668591 @default.
• W3200457141 cites W2060140468 @default.
• W3200457141 cites W2063931484 @default.
• W3200457141 cites W2093669308 @default.
• W3200457141 cites W2096657471 @default.
• W3200457141 cites W2103118548 @default.
• W3200457141 cites W2105258029 @default.
• W3200457141 cites W2110324196 @default.
• W3200457141 cites W2112778345 @default.
• W3200457141 cites W2114458368 @default.
• W3200457141 cites W2117077102 @default.
• W3200457141 cites W2141505882 @default.
• W3200457141 cites W2147597595 @default.
• W3200457141 cites W2151487996 @default.
• W3200457141 cites W2153323251 @default.
• W3200457141 cites W2155412494 @default.
• W3200457141 cites W2164438100 @default.
• W3200457141 cites W2191831187 @default.
• W3200457141 cites W2359816812 @default.
• W3200457141 cites W2400497939 @default.
• W3200457141 cites W2471488931 @default.
• W3200457141 cites W2493266198 @default.
• W3200457141 cites W2499405547 @default.
• W3200457141 cites W2533853405 @default.
• W3200457141 cites W2571321248 @default.
• W3200457141 cites W2586986292 @default.
• W3200457141 cites W2620036274 @default.
• W3200457141 cites W2750084680 @default.
• W3200457141 cites W2765907252 @default.
• W3200457141 cites W2792160356 @default.
• W3200457141 cites W2800305056 @default.
• W3200457141 cites W2801053964 @default.
• W3200457141 cites W2883158730 @default.
• W3200457141 cites W2898586645 @default.
• W3200457141 cites W2913111431 @default.
• W3200457141 cites W2914320815 @default.
• W3200457141 cites W2945817310 @default.
• W3200457141 cites W2966291742 @default.
• W3200457141 cites W2971127288 @default.
• W3200457141 cites W2972352807 @default.
• W3200457141 cites W2995432053 @default.
• W3200457141 cites W2997604421 @default.
• W3200457141 cites W2999168705 @default.
• W3200457141 cites W3043680095 @default.
• W3200457141 cites W3092088757 @default.
• W3200457141 cites W3119215383 @default.
• W3200457141 cites W3165318815 @default.
• W3200457141 cites W3172400775 @default.
• W3200457141 cites W3175273452 @default.
• W3200457141 cites W4230454892 @default.
• W3200457141 cites W4241614669 @default.
• W3200457141 cites W99631282 @default.
• W3200457141 doi "https://doi.org/10.1101/2021.09.13.21263539" @default.
• W3200457141 hasPublicationYear "2021" @default.
• W3200457141 type Work @default.
• W3200457141 sameAs 3200457141 @default.
• W3200457141 citedByCount "1" @default.
• W3200457141 countsByYear W32004571412023 @default.
• W3200457141 crossrefType "posted-content" @default.
• W3200457141 hasAuthorship W3200457141A5002305085 @default.
• W3200457141 hasAuthorship W3200457141A5004644854 @default.

• next